Electronegative electroretinogram associated with topiramate toxicity and vitelliform maculopathy

Tsui, Irena; Casper, Daniel S.; Chou, Chun Liang; Tsang, Stephen H.

doi:10.1007/s10633-007-9084-7

Cited by 16 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…She had been taking TPM 400 mg/day for 4 years 72. This case can be introduced as a human instance of electronegative ERG following TPM therapy, and is in line with the findings of Kjellstrom et al29…”

Section: Tpm Ophthalmologic Complicationssupporting

confidence: 86%

Topiramate and the vision: a systematic review

Abtahi¹,

Abtahi²,

Fazel³

et al. 2012

OPTH

101

106

View full text Add to dashboard Cite

Background and purposeTopiramate (TPM) is a sulfa-derivative monosaccharide that is used mainly for treating epilepsy and preventing migraine. Within the gamut of side effects attributable to this drug, ophthalmologic manifestations are of crucial importance. In this study, for the first time, the aim was to provide a systematic literature review regarding this issue.MethodsFor the time period 1996–2011, a PubMed search was made for the studies concerning the adverse/beneficial effects of TPM on vision. Overall, 404 citations out of a total of 2756 TPM-related studies were examined for relevance.ResultsA total of 74 relevant studies were reviewed, 65 of which comprise small observational studies describing the ophthalmic side effects of TPM in 84 patients. Of these patients, 66 were affected by ciliochoroidal effusion syndrome as the cardinal ocular side effect of TPM (17 cases of myopic shift and 49 cases of angle closure glaucoma). A comprehensive statistical analysis is provided on these 66 subjects. Other rare side effects of TPM on the vision were also reviewed, including massive choroidal effusion, ocular inflammatory reactions, visual field defects, probable effects on retina, cornea, and sclera, and neuroophthalmologic complications. In addition, a framework is provided to classify these results.DiscussionDue to the expanding spectrum of indications for the administration of TPM, neurologists and psychiatrists should be aware of its diverse ocular side effects. In conclusion, ocular complications following this drug should be taken seriously and be subjected to ophthalmic counseling.

show abstract

Section: Tpm Ophthalmologic Complicationssupporting

confidence: 86%

Topiramate and the vision: a systematic review

Abtahi¹,

Abtahi²,

Fazel³

et al. 2012

OPTH

101

106

View full text Add to dashboard Cite

show abstract

“…TPM-induced ocular inflammatoryreactions [11], retinal side effects [12], visual field defects were reported [13]. Similar to this case, several case report reveal topiramate-induced maculopathy [14][15][16]. Untreated maculopathy may cause severe and irrevisible disorder if iftopiramateis not promptly discontinued.…”

Section: Discussionsupporting

confidence: 69%

Acute Myopia Induced by Topiramate Plus Phentermine for the Treatment of Obesity

Park¹,

Lee²,

Kim³

et al. 2012

J Clin Toxicol

View full text Add to dashboard Cite

Topiramate (TPM) iscurrently used for the treatment of epilepsy, migraine prophylaxis, bipolar diseases, and post-traumatic stress disorders. Recent studies reveal that a low-dose combination of Phentermine plus controlledrelease Topiramate (PHEN/TPM CR) as an adjunct to lifestyle modification reduces body weight in obese and overweight adults without significant side effects. We are reporting the case of an overweight young girl with acute progressive myopia due to topiramate, which was being used to treat her obesity. OD OS Figure 2: Optical coherence tomography (OCT) for detection of macular oedema. Undulating profile is more prominent in the OS.

show abstract

“…Autofluorescence images were obtained using a confocal scanning-laser ophthalmoscope (cSLO, Heidelberg Retina Angiograph 2, Heidelberg Engineering, Dossenheim, Germany) by illuminating the fundus with argon laser light (488 nm) and viewing the resultant fluorescence through a band pass filter with a short wavelength cut-off at 495 nm 13 14 15 16 17 18…”

Section: Methodsmentioning

confidence: 99%

Cellular origin of fundus autofluorescence in patients and mice with a defective NR2E3 gene

Wang

Fine²,

Chang³

et al. 2009

British Journal of Ophthalmology

View full text Add to dashboard Cite

Aim-To characterize new clinical features in a family with enhanced S-cone syndrome (ESCS) and investigate the pathogenesis of these clinical features in the homozygous Nr2e3 rd7rd7 (rd7) mutant mice.Methods-Four patients from an affected family were included for genotypic and phenotypic study. Eye tissues from rd7 mice were used to detect a possible relationship between macrophages and autofluorescent material by immunohistochemistry (IHC) staining.Results-Homozygous mutation in R311Q in NR2E3 was detected in this family. Color photographs revealed that white dots do not correlate to hyperautofluorescent spots seen in autofluorescence imaging of the macula. OCT showed rosette-like lesions similar to those found in rd7 mice histology sections. From IHC analysis, we observed that F4/80 (a pan macrophage marker), and autofluorescence were co-localized to the same cells within the retina rosettes.Conclusions-Retinal structure of a young ESCS patient with homozygous R311Q mutation in the NR2E3 gene is similar to that seen in the rd7 mice. The macrophages were found to contain autofluorescent materials in the retinal rosettes of rd7 mice. Our data are consistent with macrophage infiltration contributing to the hyper-autofluorescent spots found in our patients.

show abstract

Electronegative electroretinogram associated with topiramate toxicity and vitelliform maculopathy

Cited by 16 publications

References 4 publications

Topiramate and the vision: a systematic review

Topiramate and the vision: a systematic review

Acute Myopia Induced by Topiramate Plus Phentermine for the Treatment of Obesity

Cellular origin of fundus autofluorescence in patients and mice with a defective NR2E3 gene

Contact Info

Product

Resources

About